MicroBiome Therapeutics’ Clinical Trial Data For NM504 In Type 2 Diabetes Has Been Accepted For Presentation At ICE/ENDO 2014
–MBT Previously Reported Statistically Significant Positive Topline Results from this First Double-Blind, Randomized Clinical Trial of a Microbiome Modulator for Diabetes–
BROOMFIELD, Colo., April 8, 2014 /PRNewswire/ — MicroBiome Therapeutics(TM) LLC, (MBT) today announced that data from the company’s clinical trial of microbiome modulator NM504 in development for type 2 diabetes and prediabetes has been accepted for a Poster Preview Presentation at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and The Endocrine Society.
NM504 is designed to improve glucose tolerance and other metabolic parameters by shifting the gastrointestinal (GI) microbiome. Studies have shown that type 2 diabetics typically have GI dysbiosis, or microbial imbalances, that may contribute to the metabolic dysfunction associated with the condition. MBT previously reported top-line results from the double-blind, randomized, placebo-controlled trial showing that oral administration of NM504 significantly reduced postprandial serum glucose levels and increased insulin sensitivity in subjects with prediabetes and untreated type 2 diabetes. NM504 was well tolerated in this trial.
“We are delighted that results from this first clinical trial of NM504, which represents a milestone both for MBT and the emerging field of microbiome therapy, have been accepted for a podium presentation at ICE/ENDO 2014, the most important endocrinology meeting in the world” noted Steve Orndorff, CEO of Microbiome Therapeutics. “We appreciate the opportunity to present more detailed results from this important study to diabetes experts from around the globe.”
NM504 is also being studied in a placebo-controlled, double-blinded, proof of concept trial testing its utility in combination with metformin in type 2 diabetes patients with adverse GI effects. In a published case study, NM504 demonstrated the potential to mitigate the GI side effects associated with metformin.
MBT is developing microbiome modulators that alter microbial populations and their environment in the GI tract to address serious health conditions. The company’s microbiome modulators are designed to act on multiple factors, augmenting the growth of targeted desirable bacterial strains and discouraging the growth of others. NM504 is formulated to promote microbiome shifts that positively affect metabolism and weight.
The session for the Poster Preview Presentation by MBT Chief Scientific Officer Dr. Mark Heiman is scheduled from 11:15am-11:30am CT on June 23, 2014. The poster presentation will run from 1:00pm-3:00pm the same day. ICE/ENDO 2014 will take place June 21-24, 2014 in Chicago, IL. For more information, visit www.endocrine.org/endo-2014.
About MicroBiome Therapeutics(TM
)MicroBiome Therapeutics LLC (MBT), is a clinical stage biotechnology company developing pharmaceutical and medical food products that aim to improve health status by interacting with and altering the human microbiome. MBT is developing evidence-based microbiome modulators to address serious health conditions. Lead product NM504 is being tested in clinical trials for the management of insulin sensitivity and blood glucose levels and as an adjunct to metformin in patients with prediabetes and type 2 diabetes. For more information, visit www.mbiome.com.
Contacts: Media: Steve Orndorff Barbara Lindheim CEO BLL Partners, LLC MicroBiome Therapeutics (212) 584-2276 (303) 544-2104 email@example.com
SOURCE MicroBiome Therapeutics LLC